【中金:升亚盛医药-B(06855.HK)目标价至88港元 评级“跑赢行业”】智通财经APP获悉,中金发布研报称,考虑到

智通财经
Jul 14, 2025
【中金:升亚盛医药-B(06855.HK)目标价至88港元 评级“跑赢行业”】智通财经APP获悉,中金发布研报称,考虑到利生妥获批上市及全球适应症拓展前景,维持亚盛医药-B(06855.HK)跑赢行业评级,根据DCF模型,上调目标价27.5%至88港币,较当前股价有15.3%的上行空间。7月10日,公司公告自主研发的新型Bcl-2选择性抑制剂利生妥(利沙托克拉,APG-2575)获中国国家药品监督管理局附条件批准上市,用于既往经过至少包含布鲁顿酪氨酸激酶(BTK)抑制剂在内的一种系统治疗的成人慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(CLL/SLL)患者。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10